Diffuse Large B-Cell Lymphoma, NOS · line 1 · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | None |
| ID | IND-EMERG-INFUSION-REACTION-IRR |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-DLBCL-NOS |
| Sources | SRC-CTCAE-V5 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Emergency supportive-care indication for infusion-related reaction management. time_critical=true: rapid intervention required, particularly for grade 4 anaphylaxis. Cross-disease relevance — disease_id=DIS-DLBCL-NOS used as proxy (rituximab IRRs most common); engine should fire across all monoclonal antibody indications.
Used By
No reverse references found in the YAML corpus.